EDISON, N.J. - Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company engaged in the development of drugs for NASH and other chronic diseases, announced on Tuesday the addition of Michael Purcell to its Board of Directors. Purcell, with a career spanning over three decades at Deloitte & Touche LLP, brings extensive experience in financial advisory and audit services to the company.
Purcell's professional background includes a tenure as an Audit Partner at Deloitte from 1979 to 2015 and a consultant role from 2015 to 2017. His expertise extends to serving emerging growth companies as a financial advisor. Purcell holds a CPA certification and has been a board member at various financial institutions and healthcare companies, including Tabula Rasa HealthCare (NASDAQ:TRHC), Inc., CFG Bank, Hyperion Bank, and International Money Express (NASDAQ:IMXI), Inc. His academic contributions are reflected in his board positions at several educational and community organizations.
Hepion's lead drug candidate, rencofilstat, has been recognized by the FDA with Fast Track and Orphan Drug designations for NASH and hepatocellular carcinoma (HCC), respectively. The company also leverages an AI/ML platform to enhance drug development efficiency.
The appointment of Purcell is a strategic move for Hepion Pharmaceuticals as it navigates the complexities of clinical trials and seeks to strengthen its corporate governance. This news is based on a press release statement from Hepion Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.